The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1214
August 1, 2005
View Complete Issue         Table of Contents 2019 
Ropinirole for Restless Legs Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ropinirole for Restless Legs Syndrome
August 1, 2005 (Issue: 1214)
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ropinirole for Restless Legs Syndrome
Article code: 1214b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.